Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes

References

• Al-Salami H, Butt G, Fawcett JP, Tucker IG, Golocorbin-Kon S, Mikov M. 2008a. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet. 33:101–106.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Fawcett PJ, Golocorbin-Kon S, Mikov I, Mikov M. 2009. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 34:43–50.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Golocorbin-Kon S, Mikov M. 2012. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 37:99–108.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. 2008b. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30:107–113.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Mikov M. 2008c. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30:107–113.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S, Mikov M. 2008d. Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch Drug Inf. 1:35–41.
   PubMedGoogle Scholar
• Al-Salami H, Butt G, Tucker IG, Mikov M. 2008e. The influence of pre-treatment with probiotics on the in vitro ileal permeation of the antidiabetic drug gliclazide, in healthy and diabetic rats. Drug Metabolism Reviews. 40:81–82.
   Web of Science ®Google Scholar
• Al-Salami H, Grant B, Ian T, Mikov M. 2008f. The influence of probiotics pre-treatment, on the ileal permeation of gliclazide, in healthy and diabetic rats. The Archives of Drug Information. 1:35–41.
   PubMedGoogle Scholar
• Al-Salami H, Kansara H, King J, Morar B, Jayathilaka B, Fawcett PJ, Mikov M. 2007. Bile acids: a bitter sweet remedy for diabetes. The New Zealand Pharmacy Journal. 27:17–20.
   Google Scholar
• Arifin DR, Long CM, Gilad AA, Alric C, Roux S, Tillement O, et al. 2011. Trimodal gadolinium-gold microcapsules containing pancreatic islet cells restore normoglycemia in diabetic mice and can be tracked by using US, CT, and positive-contrast MR imaging. Radiology. 260:790–798.
   PubMed Web of Science ®Google Scholar
• Arifin DR, Manek S, Call E, Arepally A, Bulte JW. 2012. Microcapsules with intrinsic barium radiopacity for immunoprotection and X-ray/CT imaging of pancreatic islet cells. Biomaterials. 33:4681–4689.
   PubMed Web of Science ®Google Scholar
• Calasan J, Al-Salami H, Mikov M. 2012. Bile acids and probiotics could help treating diabetes. Febs Journal. 279:267–267.
   Web of Science ®Google Scholar
• George M, Abraham TE. 2006. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan–a review. J Control Release. 114:1–14.
   PubMed Web of Science ®Google Scholar
• Goh CH, Heng PWS, Chan LW. 2012. Alginates as a useful natural polymer for microencapsulation and therapeutic applications. Carbohydrate Polymers. 88:1–12.
   Web of Science ®Google Scholar
• Lalic-Popovic M, Vasovic V, Milijasevic B, Golocorbin-Kon S, Al-Salami H, Mikov M. 2013. Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat. J Diabet Res. 2013:598603.
   PubMed Web of Science ®Google Scholar
• Mikov M, Al-Salami H, Golocorbin-Kon G. 2012. Potentials and Limitations of Bile Acids and Probiotics in Diabetes Mellitus.
   Google Scholar
• Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett JP. 2008. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 33:137–142.
   PubMed Web of Science ®Google Scholar
• Mikov M, Boni NS, Al-Salami H, Kuhajda K, Kevresan S, Fawcett JP. 2006. Pharmacokinetics and hypoglycaemic effect of 3 alpha, 7 alpha-dihydroxy-12-oxo-5beta-cholanate (MKC) in diabetic rat. Febs Journal. 273:210–210.
   Web of Science ®Google Scholar
• Mikov M, Boni NS, Al-Salami H, Kuhajda K, Kevresan S, Golocorbin-Kon S, Fawcett JP. 2007. Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. Eur J Drug Metab Pharmacokinet. 32:7–12.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, Golocorbin-Kon S, et al. 2014a. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech. 16:45–52.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Arfuso F, Al-Salami H. 2014b. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells. Artif Cells Nanomed Biotechnol. 11:1–7.
   Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, et al. 2014c. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Des Devel Ther. 8:1003–1012.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, et al. 2014d. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Devel Ther. 8:1221–1230.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. 2014e. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov. 9:150–157.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. 2014f. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol. 0:1–8.
   Google Scholar
• Negrulj R, Mooranian A, Al-Salami H. 2013. Potentials and limitations of bile acids in type 2 diabetes mellitus: applications of microencapsulation as a novel oral delivery system. J Endocrinol Diabet Mellitus. 1:49–59.
   Google Scholar
• Takka S, Cali AG. 2012. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol. 17:23–29.
   PubMed Web of Science ®Google Scholar
• Tam SK, Dusseault J, Polizu S, Ménard M, Hallé J-P, Yahia LH. 2005. Physicochemical model of alginate–poly-L-lysine microcapsules defined at the micrometric/nanometric scale using ATR-FTIR, XPS, and ToF-SIMS. Biomaterials. 26:6950–6961.
   PubMed Web of Science ®Google Scholar
• Wu R, Zhang W, Liu B, Gao J, Xiao X-Q, Zhang F, et al. 2013. Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets. Dig Dis Sci. 58:163–171.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Matsuzawa Y. 2009. Where are we with probucol: a new life for an old drug? Atherosclerosis. 207:16–23.
   PubMed Web of Science ®Google Scholar